Abdulrazaq S. Al-Jazairi,
Pharm.D., MBA, FCCP, BCPS (AQ-Cardiology)
Director, Pharmaceutical Care Division
Chairman, Saudi Scientific Pharmacy Board
Consultant Clinical Pharmacist, Cardiology
King Faisal Specialist Hospital & Research Centre- Riyadh Saudi Arabia
Dr. Al-Jazairi is a Clinical Pharmacy Consultant in the field of Cardiovascular Pharmacotherapy and the Director of Pharmaceutical Care Division at the prestigious King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh Saudi Arabia. He received his Doctor of Pharmacy degree from Campbell University at Buies Creek, North Carolina, USA, and a general Pharmacy Practice Residency at Duke University Medical Center (DUMC), Durham, NC. In 2000, Dr. Al-Jazairi completed a two-year Specialty Residency in Cardiovascular Pharmacotherapy from Philadelphia College of Pharmacy (PCP), University of the Sciences in Philadelphia in conjunction with the Hospital University of Pennsylvania (HUP), Philadelphia, Pennsylvania. More recently, 2014, Dr. Al-Jazairi earned a Master degree in Pharmaceutical and Healthcare Business from Mayes College, University of the Sciences in Philadelphia. Dr. Al-Jazairi is a board certified pharmacotherapy specialist with Cardiology added-qualification.

Dr. Al-Jazairi has more than 30 original research publications, and delivered many national and international presentations. Dr. Al-Jazairi is the Lead Founder of the Saudi Clinical Pharmacy Society, 2018. Currently he is chairing the Saudi Scientific Pharmacy Board. He is an editorial board member of prime journals, including Annals of Pharmacotherapy and the Annals of Saudi Medicine, for more than 10 years. He sets in several committees in Saudi-FDA, Saudi Commission for Health Specialties and Saudi Health Council. He is also chaired the Clinical Research Committee in the Research Center at KFSHRC- Riyadh for the three terms. Dr. Al-Jazairi enjoys training students and residents in Cardiology and Evidence-based Medicine. Dr. Al-Jazairi is the Director of the first and only Cardiology Residency Program accredited by ASHP outside the States, at King Faisal Specialist Hospital and Research Center (KFSH&RC). He also serves as an Associate Professor, School of Pharmacy in Qassim University, Al-Faisal University, and adjunct Assistant Professor in Princess Nora University, Riyadh, Saudi Arabia.

Dr. Ibrahim M. Salman
Assistant Professor of Physiology and Pharmacology
+ 966 11 215 8819
My primary research goal is to better understand how the autonomic nervous system controls cardiovascular functions, both under normal conditions and in the presence of pathological disorders that elevate blood pressure. A myriad of clinical conditions presents with high blood pressure including, but not limited to, essential hypertension, chronic kidney disease, obesity and sleep apnea. As these conditions continue to become more prevalent, the cardiovascular disease that accompanies them also becomes a major health issue worldwide. In fact, many of these conditions alter how the brain controls blood pressure, but the mechanisms underlying this effect are poorly understood. We believe that the disease process progressively impacts the autonomic neuroregulation of cardiovascular function, thereby contributing central deficits in both tonic and reflex control of blood pressure. To systematically investigate this, we employ a multi-disciplinary research approach ranging from whole animal physiology and pharmacology to electrophysiology (e.g., whole fiber neural recordings and neurostimulation). These experimental strategies are generally integrative and allow for acute and chronic measurements of blood pressure, organ perfusion and whole nerve activity (e.g., vagus nerve, aortic nerve and a range of sympathetic nerve beds) in conscious and anesthetized rats. A major focus of our current research activity is elucidating the impact of neural laterality on central integration of baroreceptor afferent input and how this would modulate overall reflex hemodynamic control under normal and high blood pressure conditions. A second recent focus of our research is to understand the pathophysiological link between neuromodulation of renal nerve activity and the expression of cardiorespiratory functions in the Zucker fat rat model of obesity-related hypertension and sleep apnea. A comprehensive research profile can be found here.

Dr. Mohammed Khanfar
Associate Professor of Medicinal Chemistry
+ 966 11 215 7664
Dr. Khanfar’s research involves the use of state of the art pharmaceutical, computational and medicinal chemistry technologies to design, synthesize and evaluate new molecules for the treatment of human disease and to probe biological systems with a particular emphasis on cancer and neurodegenerative diseases. Dr. Khanfar’s research focuses on developing novel computational and molecular modeling technologies to understand protein-drug interactions and to design and discover novel and active drugs. His research team uses the many existing methods of computer-aided drug design, such as multidimensional QSAR, docking, conformational analysis, and pharmacophore modeling for understanding drug action and designing and discovering new therapeutics. Alternatively, Dr. Khanfar applied synthetic and medicinal chemistry techniques to design and synthesis new therapeutics targeting oncology and neurodegenerative diseases. For example, Dr. Khanfar synthesized very potent mTOR inhibitors as anticancer agents and selective SIRT2 inhibitors targeting Huntington's disease.

Research interests: My research focuses on investigating mechanisms underlying the antihypertensive effects of drugs, xenobiotics or plant-based medicinal compounds, and assessing pathways altering endothelial and non-endothelial dependent signalling mechanisms within the vasculature. This involves the use of a range of experimental approaches including in-vitro isolated tissue preparation and organ bath studies as well as in-vivo monitoring of cardiovascular parameters in conscious and anaesthetized animal studies. Furthermore, my work involves neurostimulation of selected neurovascular beds in different rats to assess hemodynamics and altered target-organ perfusion in many pathophysiological or drug-induced conditions. Another area of my research is dedicated to investigating modulation of arterial functionality in various cardiovascular pathological conditions (e.g., hypertension, diabetes, chronic kidney disease) and its potential contribution to the increased risk of morbidity and mortality in this population. We also employ the use of engineering elastic modulus and stress-strain relationship to assess vascular stiffness. This is backed up by measurements of tissue and biochemical pathological markers and comprehensive histomorphometric analyses of histological sections acquired from arterial specimens. To this end, we assess changes in structural arterial components including, but not limited to, elastin, collagen and calcium in response to elevated blood pressure. My current project activity involves investigation of regional functional and structural aortic functions in insulin-resistant high fat diet rat model. For a comprehensive list of publications, please refer to the following link.